Numans Health Food Holdings Company Limited (NUMANS) reported a mixed first-half 2026 performance, with bottom-line strength driven by investment income offsetting softer operating results.
Revenue and Gross Margin • Group revenue fell 22.0% year on year to RMB 72.66 million, reflecting a 48.3% contraction in cross-border e-commerce sales and a 61.7% drop in sales to regional distributors amid tougher PRC consumer demand and stricter e-commerce compliance rules. • Algal oil DHA products remained dominant, contributing 95.1% of total sales. Unit volume declined to 323,000 (-33.5%), yet average selling price rose 12.8% to RMB 214.10 per unit, aided by product-mix shifts and lower gross-margin guarantee deductions. • Gross profit contracted 25.3% to RMB 46.50 million; gross margin narrowed to 64.0% from 66.8% a year earlier.
Earnings Lifted by Investment Activity • Other gains swung to a RMB 45.56 million profit (1H25: RMB 0.45 million loss), largely from a RMB 68.04 million realised gain on partial disposal of Lenovo Group shares and a RMB 20.22 million unrealised loss on listed equity holdings. • Reported profit attributable to shareholders rose to RMB 48.87 million from RMB 2.13 million. Excluding investment-related gains and associated taxes, underlying profit was approximately RMB 5.20 million.
Cost Structure and Expenses • Selling and distribution expenses fell 27.8% to RMB 28.07 million, or 38.6% of revenue (1H25: 41.7%), following lower marketing spend in line with reduced sales. • Administrative and other operating expenses declined 15.2% to RMB 12.32 million, helped by reduced professional fees.
Balance Sheet and Liquidity • Cash and cash equivalents stood at RMB 278.70 million (31 Dec 2025: RMB 401.48 million), after redeploying HK$296.0 million of idle cash into listed equities (XtalPi and Lenovo). • Net current assets reached RMB 494.69 million; current ratio moderated to 12.6x from 28.9x due to a RMB 21.98 million final dividend provision and higher tax payables. • The Group remains debt-free and recorded no significant capital commitments or pledged assets.
Dividend and Outlook • The board declared no interim dividend. • Management reiterated confidence in China’s long-term nutrition market, citing rising health awareness and supportive population policies, and plans to continue brand-building and distribution optimisation.
Regulatory and Compliance • The company maintained full compliance with Hong Kong’s Corporate Governance Code, aside from combining chairman and CEO roles. • No material post-period events were reported.
Strategic Investments • Listed equity holdings totalled RMB 165.71 million at 30 Jun 2026 (30.0% of total assets). • Subsequent to period-end, market value of XtalPi and Lenovo positions implied an aggregate unrealised loss of approximately HK$6.8 million versus cost.
NUMANS’ interim results highlight the volatility introduced by its new equity investment programme, which boosted reported earnings amid challenging core operating conditions. The company plans to deploy remaining IPO proceeds of RMB 55.60 million primarily for marketing, channel expansion and a future Hong Kong retail presence through 2027.